(Reuters) – Public-benefit corporation Lykos Therapeutics said on Thursday it would reduce its workforce by 75%.
The company said it was addressing the U.S. FDA’s recent decision to decline approval for its MDMA-based PTSD treatment.
(Reporting by Christy Santhosh; Editing by Pooja Desai)
Comments